Inhibition of discoidin domain receptor 1 reduces collagen-mediated tumorigenicity in pancreatic ductal adenocarcinoma

Kristina Y. Aguilera, Huocong Huang, Wenting Du, Moriah M. Hagopian, Zhen Wang, Stefan Hinz, Tae Hyun Hwang, Huamin Wang, Jason B. Fleming, Diego H. Castrillon, Xiaomei Ren, Ke Ding, Rolf A. Brekken

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The extracellular matrix (ECM), a principal component of pancreatic ductal adenocarcinoma (PDA), is rich in fibrillar collagens that facilitate tumor cell survival and chemoresistance. Discoidin domain receptor 1 (DDR1) is a receptor tyrosine kinase that specifically binds fibrillar collagens and has been implicated in promoting cell proliferation, migration, adhesion, ECM remodeling, and response to growth factors. We found that collagen-induced activation of DDR1 stimulated protumorigenic signaling through protein tyrosine kinase 2 (PYK2) and pseudopodium-enriched atypical kinase 1 (PEAK1) in pancreatic cancer cells. Pharmacologic inhibition of DDR1 with an ATP-competitive orally available small-molecule kinase inhibitor (7rh) abrogated collagen-induced DDR1 signaling in pancreatic tumor cells and consequently reduced colony formation and migration. Furthermore, the inhibition of DDR1 with 7rh showed striking efficacy in combination with chemotherapy in orthotopic xenografts and autochthonous pancreatic tumors where it significantly reduced DDR1 activation and downstream signaling, reduced primary tumor burden, and improved chemoresponse. These data demonstrate that targeting collagen signaling in conjunction with conventional cytotoxic chemotherapy has the potential to improve outcome for pancreatic cancer patients.

Original languageEnglish (US)
Pages (from-to)2473-2485
Number of pages13
JournalMolecular Cancer Therapeutics
Volume16
Issue number11
DOIs
StatePublished - Nov 1 2017

Fingerprint

Adenocarcinoma
Collagen
Fibrillar Collagens
Pancreatic Neoplasms
Focal Adhesion Kinase 1
Extracellular Matrix
Phosphotransferases
Neoplasms
Pseudopodia
Receptor Protein-Tyrosine Kinases
Combination Drug Therapy
Tumor Burden
Heterografts
Cell Movement
Discoidin Domain Receptor 1
Cell Survival
Intercellular Signaling Peptides and Proteins
Adenosine Triphosphate
Cell Proliferation
Drug Therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Inhibition of discoidin domain receptor 1 reduces collagen-mediated tumorigenicity in pancreatic ductal adenocarcinoma. / Aguilera, Kristina Y.; Huang, Huocong; Du, Wenting; Hagopian, Moriah M.; Wang, Zhen; Hinz, Stefan; Hwang, Tae Hyun; Wang, Huamin; Fleming, Jason B.; Castrillon, Diego H.; Ren, Xiaomei; Ding, Ke; Brekken, Rolf A.

In: Molecular Cancer Therapeutics, Vol. 16, No. 11, 01.11.2017, p. 2473-2485.

Research output: Contribution to journalArticle

Aguilera, Kristina Y. ; Huang, Huocong ; Du, Wenting ; Hagopian, Moriah M. ; Wang, Zhen ; Hinz, Stefan ; Hwang, Tae Hyun ; Wang, Huamin ; Fleming, Jason B. ; Castrillon, Diego H. ; Ren, Xiaomei ; Ding, Ke ; Brekken, Rolf A. / Inhibition of discoidin domain receptor 1 reduces collagen-mediated tumorigenicity in pancreatic ductal adenocarcinoma. In: Molecular Cancer Therapeutics. 2017 ; Vol. 16, No. 11. pp. 2473-2485.
@article{0724f47a43434aa894d74ca701f7b4e2,
title = "Inhibition of discoidin domain receptor 1 reduces collagen-mediated tumorigenicity in pancreatic ductal adenocarcinoma",
abstract = "The extracellular matrix (ECM), a principal component of pancreatic ductal adenocarcinoma (PDA), is rich in fibrillar collagens that facilitate tumor cell survival and chemoresistance. Discoidin domain receptor 1 (DDR1) is a receptor tyrosine kinase that specifically binds fibrillar collagens and has been implicated in promoting cell proliferation, migration, adhesion, ECM remodeling, and response to growth factors. We found that collagen-induced activation of DDR1 stimulated protumorigenic signaling through protein tyrosine kinase 2 (PYK2) and pseudopodium-enriched atypical kinase 1 (PEAK1) in pancreatic cancer cells. Pharmacologic inhibition of DDR1 with an ATP-competitive orally available small-molecule kinase inhibitor (7rh) abrogated collagen-induced DDR1 signaling in pancreatic tumor cells and consequently reduced colony formation and migration. Furthermore, the inhibition of DDR1 with 7rh showed striking efficacy in combination with chemotherapy in orthotopic xenografts and autochthonous pancreatic tumors where it significantly reduced DDR1 activation and downstream signaling, reduced primary tumor burden, and improved chemoresponse. These data demonstrate that targeting collagen signaling in conjunction with conventional cytotoxic chemotherapy has the potential to improve outcome for pancreatic cancer patients.",
author = "Aguilera, {Kristina Y.} and Huocong Huang and Wenting Du and Hagopian, {Moriah M.} and Zhen Wang and Stefan Hinz and Hwang, {Tae Hyun} and Huamin Wang and Fleming, {Jason B.} and Castrillon, {Diego H.} and Xiaomei Ren and Ke Ding and Brekken, {Rolf A.}",
year = "2017",
month = "11",
day = "1",
doi = "10.1158/1535-7163.MCT-16-0834",
language = "English (US)",
volume = "16",
pages = "2473--2485",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Inhibition of discoidin domain receptor 1 reduces collagen-mediated tumorigenicity in pancreatic ductal adenocarcinoma

AU - Aguilera, Kristina Y.

AU - Huang, Huocong

AU - Du, Wenting

AU - Hagopian, Moriah M.

AU - Wang, Zhen

AU - Hinz, Stefan

AU - Hwang, Tae Hyun

AU - Wang, Huamin

AU - Fleming, Jason B.

AU - Castrillon, Diego H.

AU - Ren, Xiaomei

AU - Ding, Ke

AU - Brekken, Rolf A.

PY - 2017/11/1

Y1 - 2017/11/1

N2 - The extracellular matrix (ECM), a principal component of pancreatic ductal adenocarcinoma (PDA), is rich in fibrillar collagens that facilitate tumor cell survival and chemoresistance. Discoidin domain receptor 1 (DDR1) is a receptor tyrosine kinase that specifically binds fibrillar collagens and has been implicated in promoting cell proliferation, migration, adhesion, ECM remodeling, and response to growth factors. We found that collagen-induced activation of DDR1 stimulated protumorigenic signaling through protein tyrosine kinase 2 (PYK2) and pseudopodium-enriched atypical kinase 1 (PEAK1) in pancreatic cancer cells. Pharmacologic inhibition of DDR1 with an ATP-competitive orally available small-molecule kinase inhibitor (7rh) abrogated collagen-induced DDR1 signaling in pancreatic tumor cells and consequently reduced colony formation and migration. Furthermore, the inhibition of DDR1 with 7rh showed striking efficacy in combination with chemotherapy in orthotopic xenografts and autochthonous pancreatic tumors where it significantly reduced DDR1 activation and downstream signaling, reduced primary tumor burden, and improved chemoresponse. These data demonstrate that targeting collagen signaling in conjunction with conventional cytotoxic chemotherapy has the potential to improve outcome for pancreatic cancer patients.

AB - The extracellular matrix (ECM), a principal component of pancreatic ductal adenocarcinoma (PDA), is rich in fibrillar collagens that facilitate tumor cell survival and chemoresistance. Discoidin domain receptor 1 (DDR1) is a receptor tyrosine kinase that specifically binds fibrillar collagens and has been implicated in promoting cell proliferation, migration, adhesion, ECM remodeling, and response to growth factors. We found that collagen-induced activation of DDR1 stimulated protumorigenic signaling through protein tyrosine kinase 2 (PYK2) and pseudopodium-enriched atypical kinase 1 (PEAK1) in pancreatic cancer cells. Pharmacologic inhibition of DDR1 with an ATP-competitive orally available small-molecule kinase inhibitor (7rh) abrogated collagen-induced DDR1 signaling in pancreatic tumor cells and consequently reduced colony formation and migration. Furthermore, the inhibition of DDR1 with 7rh showed striking efficacy in combination with chemotherapy in orthotopic xenografts and autochthonous pancreatic tumors where it significantly reduced DDR1 activation and downstream signaling, reduced primary tumor burden, and improved chemoresponse. These data demonstrate that targeting collagen signaling in conjunction with conventional cytotoxic chemotherapy has the potential to improve outcome for pancreatic cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=85032840976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032840976&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-16-0834

DO - 10.1158/1535-7163.MCT-16-0834

M3 - Article

C2 - 28864681

AN - SCOPUS:85032840976

VL - 16

SP - 2473

EP - 2485

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 11

ER -